ENDRA Life Sciences(US:NDRA)2025-05-15 20:58Financial Performance - ENDRA's cash burn for Q1 2025 was $1.2 million, a significant improvement from $1.7 million in Q1 2024, reflecting a reduction of approximately 29%[11] - Total operating expenses for Q1 2025 were $1.5 million, nearly a 50% decrease compared to $2.8 million in the same period last year[12] - The net loss for Q1 2025 was $1.0 million, compared to a net loss of $2.8 million in Q1 2024, indicating a reduction of approximately 64%[12] - ENDRA had $2.1 million in cash and cash equivalents as of March 31, 2025, which increased to $2.5 million by April 30, 2025, after raising $0.8 million[13] Product Development and Strategy - The company is conducting a multisite pilot study with over 100 subjects to assess the liver fat measurement capabilities of the TAEUS Liver system against MRI-PDFF[6] - ENDRA plans to offer the TAEUS Liver device through a subscription model to facilitate market penetration and eliminate upfront capital investments[8] - The redesigned TAEUS Liver system aims to improve usability, performance, and affordability, with a multicenter clinical trial expected to enroll approximately 250 subjects[5] Market Focus and Intellectual Property - The company has identified four key customer segments for TAEUS, including pharmaceutical companies and primary care providers, to maximize impact[5] - ENDRA was issued two new patents in China, bringing its total patent portfolio to 84, enhancing its intellectual property position[10] - ENDRA's strategic pivot focuses on addressing the urgent healthcare challenge of metabolic diseases, which affect over 2 billion people globally[3]